Gong JH, Maki G, Klingemann HG.
Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells.Leukemia. 1994 Apr;8(4):652-8.
Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H.Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy. 2008;10(6):625-32.
Tonn T, Becker S, Esser R, Schwabe D, Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92.J Hematother Stem Cell Res. 2001 Aug;10(4):535-44.
Maki G, Klingemann HG, Martinson JA, Tam YK.
Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92.
J Hematother Stem Cell Res. 2001 Jun;10(3):369-83
Isobe Y, Sugimoto K, Yang L, Tamayose K, Egashira M, Kaneko T, Takada K, Oshimi K .
Epstein-Barr Virus Infection of Human Natural Killer Cell Lines and Peripheral Blood Natural Killer Cells.
Cancer Res 2004; 64(6):2167–74
Cord C. Uphoff, Sabine A. Denkmann, Klaus G. Steube, Hans G. Drexler, "Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in Human and Other Primate Cell Lines", BioMed Research International, vol. 2010, Article ID 904767, 23 pages, 2010. https://doi.org/10.1155/2010/904767
Established from the peripheral blood of a 50-year-old man with non-Hodgkin lymphoma (large granular lymphocytic) in 1992. Cells were described as having azurophilic granula and strong cytotoxic NK activity. Parts of the EBV genome can be detected by PCR analysis.
According to the general statement of the ZKBS on the risk assessment of established human cell lines immortalised with Epstein-Barr virus (EBV) (ref. 402.45244.0046, May 2012), these were briefly assigned to risk group 2 as a precaution.
In the meantime, the results of a lymphocyte transformation test have been submitted.
DSMZ no.: ACC 488
PCR: EBV +, HBV -, HCV -, HIV -, HTLV-I/II -, SMRV -
